中国药物警戒 ›› 2023, Vol. 20 ›› Issue (5): 585-587.
DOI: 10.19803/j.1672-8629.20220352

• 安全与合理用药 • 上一篇    下一篇

来那度胺致高级别B细胞淋巴瘤患者似癫痫样发作1例分析

彭苗新1, 王艳琼2△, 许佩佩1, 杨永公1,*   

  1. 1南京大学医学院附属鼓楼医院血液科,江苏 南京 210008;
    2南京医科大学鼓楼临床医学院血液科,江苏 南京 210008
  • 收稿日期:2022-12-12 出版日期:2023-05-15 发布日期:2023-05-16
  • 通讯作者: *杨永公,男,硕士,副主任医师,血液病。E-mail：915834491@qq.com
  • 作者简介:彭苗新,女,硕士,主治医师,血液病。Δ为并列第一作者。

Analysis of epileptic seizures induced by lenalidomide with high-grade B cell lymphoma

PENG Miaoxin1, WANG Yanqiong2△, XU Peipei1, YANG Yonggong1,*   

  1. 1Department of Hematology, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing Jiangsu 210008, China;
    2Department of Hematology, Nanjing Drum Tower Hospital, Clinical College of Nanjing Medical University, Nanjing Jiangsu 210008, China
  • Received:2022-12-12 Online:2023-05-15 Published:2023-05-16

PDF (PC)

86

摘要： 目的 探讨来那度胺应用于晚期肿瘤老年患者时的神经相关不良反应。方法 结合相关文献,分析1例晚期肿瘤老年患者服用来那度胺10 mg不久后出现似癫痫样发作的神经相关不良反应。结果 患者服用来那度胺10 mg后出现短暂性似癫痫样抽搐发作,伴小便失禁,意识不清,1~2 min后患者自行逐渐缓解,停用来那度胺后未再发生上述中枢神经系统症状。20余天后再次服用10 mg来那度胺,患者再次出现同第1次的短暂性意识丧失伴抽搐,停药后好转。结论 来那度胺是近年难治复发淋巴瘤治疗的新药,临床医师应用时需警惕在晚期肿瘤老年患者中该药的中枢神经系统不良反应。

关键词: 来那度胺, 淋巴瘤, 中枢神经系统, 癫痫, 药品不良反应

Abstract: Objective To explore neuro-related adverse reactions of lenalidomide in elderly patients with advanced tumors. Methods One case of neuro-related adverse reactions that resembled epileptic-like seizures shortly after the administration of lenalidomide 10 mg in an elderly patient with advanced tumors was analyzed by referring to literature. Results After taking lenalidomide 10 mg, the patient presented with convulsion like transient seizures with urinary incontinence and unconsciousness, which were gradually alleviated on their own after one to two minutes, and no more CNS symptoms occurred after discontinuation of lenalidomide. More than twenty days later, the patient resumed 10 mg of lenalidomide and experienced transient loss of consciousness with convulsions a second time, but the symptoms were improved after withdrawal. Conclusion Lenalidomide is a new drug for the treatment of refractory recurrent lymphoma in recent years. Clinicians should be alert to the adverse reactions of the drug involving the central nervous system when prescribing it to elderly patients with advanced tumors.

Key words: lenalidomide, lymphoma, central nervous system, epileptic, adverse drug reaction

中图分类号: